春节后,中国创新药的BD(业务拓展)热度不减,仅3月4日上午就有两笔BD交易官宣。 3月4日,港股制药龙头中国生物制药(01177.HK)与全球跨国制药巨头赛诺菲联合宣布,双方就全球首创JAK/ROCK双靶点抑制剂罗伐昔替尼,达成独家全球许可协议。 根据协议,中国生物制药及子公司正大天晴药业将授予赛诺菲该产品在全球范围内开发、生产与商业化的独家权利,同时将获得1.35亿美元的首付款以及最高...
Source Link春节后,中国创新药的BD(业务拓展)热度不减,仅3月4日上午就有两笔BD交易官宣。 3月4日,港股制药龙头中国生物制药(01177.HK)与全球跨国制药巨头赛诺菲联合宣布,双方就全球首创JAK/ROCK双靶点抑制剂罗伐昔替尼,达成独家全球许可协议。 根据协议,中国生物制药及子公司正大天晴药业将授予赛诺菲该产品在全球范围内开发、生产与商业化的独家权利,同时将获得1.35亿美元的首付款以及最高...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.